The Model Alone Will Not Lead to Productivity Gains

Every major technology wave follows a similar pattern: early adopters embrace a new technology, productivity gains fail to deliver to the high expectations but eventually improve once organizations appropriately adapt their operating models to incorporate the new technology. Modeling in bioprocessing is moving through this transition.

Hybrid modeling is increasingly recognized as a cornerstone technology to deliver efficient process knowledge that underpins QbD. Yet while the field debates model accuracy and benchmarks one model against another, it risks repeating the same mistake that delayed returns from computing and AI: almost all effort is on the model, almost none on the required system around it.

The talk builds the case for what the system requires, from insights and recommendations grounded in uncertainty quantification, through consistent QbD-native methodology and stage-specific workflows, to the enterprise operating envelope that makes any of it usable in a regulated environment. Modeling focused on utility vs. accuracy. As AI accelerates drug discovery and fills development pipelines with new molecules, CMC becomes the binding constraint. The next competitive edge in bioprocessing will not come from a better model. It will come from the system that best leverages it.